Cited by 134Adrenal and Paraganglionic TumorsAdrenal Hormones and DisordersRenal cell carcinoma treatment

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection

Open access

Terzolo, M, Baudin, A E, Ardito, A, Kroiss, M, Leboulleux, S, Daffara, F, Perotti, P, Feelders, R A, deVries, J H, Zaggia, B, De Francia, S, Volante, M, Haak, H R, Allolio, B, Al Ghuzlan, A, Fassnacht, M, Berruti, A·2013·European Journal of Endocrinology

DOI 10.1530/eje-13-0242

Open this paper in CoChat — free account Open PDF

Abstract

CONTEXT: Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC). A correlation between mitotane concentrations and patient outcome has not been demonstrated in an adjuvant setting. OBJECTIVE: To compare recurrence-free survival (RFS) in patients who reached and maintained mitotane concentrations ≥ 1 4 mg/l vs patients who did not. DESIGN AND SETTING: Retrospective analysis at six referral European centers. PATIENTS: Patients with ACC who were radically resected between 1995 and 2009 and were treated adjuvantly with mitotane targeting concentrations of 14-20 mg/l. MAIN OUTCOME MEASURES: RFS (primary) and overall survival (secondary). RESULTS: Of the 122 patients included, 63 patients (52%) reached and maintained during a median follow-up of 36 months the target mitotane concentrations (group 1) and 59 patients (48%) did not (group 2). ACC recurrence was observed in 22 patients of group 1 (35%) and 36 patients in group 2 (61%). In multivariable analysis, the maintenance of target mitotane concentrations was associated with a significantly prolonged RFS (hazard ratio (HR) of recurrence: 0.418, 0.22-0.79; P=0.007), while the risk of death was not significantly altered (HR: 0.59, 0.26-1.34; P=0.20). Grades 3-4 toxicity was observed in 11 patients (9%) and was managed with temporary mitotane discontinuation. None of the patients discontinued mitotane definitively for toxicity. CONCLUSIONS: Mitotane concentrations ≥ 14 mg/l predict response to adjuvant treatment being associated with a prolonged RFS. A monitored adjuvant mitotane treatment may benefit patients after radical removal of ACC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1530/eje-13-0242

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920 · cited 2×
“All diagnoses were confirmed by experienced pathologists according to the Weiss criteria with a score of 3, or more, identifying malignancy (18, 19).”
BackgroundMethod
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Faßnacht, M., Terzolo, M., Allolio, B., Baudin, É., Haak, H. R., Berruti, A., Welin, S., Schade‐Brittinger, C., Lacroix, A., Jarząb, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 874
Self-citation
Pathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818 · cited 2×
“All diagnoses were confirmed by experienced pathologists according to the Weiss criteria with a score of 3, or more, identifying malignancy (18, 19).”
BackgroundMethod
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Malin, J. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 799
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Self-citation
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Faßnacht, M., Daffara, F., Tauchmanovà, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 759
Self-citation
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713 · cited 1×
“RFS is increasingly considered as a valid surrogate endpoint for OS in adjuvant trials being closely related to the efficacy of adjuvant treatment, whereas OS is usually also affected by the treatment adopted upon progression (26, 27).”
Background
Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a Revised TNM Classification
Fassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citation
Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group
Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C. (2008) · Cancer · doi:10.1002/cncr.23886 · Cited by 493

Show all 31 references

Research works printed but not linked: 2

1959, Transactions of the Association of American Physicians, 72, 341
2009, Journal of Clinical Oncology, 20, 4619

Sorted by citations

European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
Faßnacht, M., Dekkers, O. M., Else, T., Baudin, É., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assié, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 976
Self-citation
Adrenocortical carcinoma
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Faßnacht, M., Assié, G., Baudin, É., Eisenhofer, G., de la Fouchardière, C., Haak, H. R., de Krijger, R. R., Porpiglia, F., Terzolo, M., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2099 · Cited by 446
Self-citation
Update in Adrenocortical Carcinoma
Faßnacht, M., Kroiß, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414
Self-citation
Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells
Sbiera, S., Leich, E., Liebisch, G., Sbiera, I., Schirbel, A., Wiemer, L., Matysik, S., Eckhardt, C., Gardill, F., Gehl, A., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1367 · Cited by 194
Self-citation
Adrenocortical carcinoma — towards genomics guided clinical care
Crona, J., & Beuschlein, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0221-7 · Cited by 142
Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma
Kim, Y., Margonis, G. A., Prescott, J. D., Tran, T. B., Postlewait, L. M., Maithel, S. K., Wang, T. S., Evans, D. B., Hatzaras, I. S., Shenoy, R. S., et al. (2015) · JAMA Surgery · doi:10.1001/jamasurg.2015.4516 · Cited by 131
Management of adrenal cancer: a 2013 update
Terzolo, M., Daffara, F., Ardito, A., Zaggia, B., Basile, V., Ferrari, L., & Berruti, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-013-0049-2 · Cited by 109
Self-citation
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
Terzolo, M., Faßnacht, M., Perotti, P., Libé, R., Kaštelan, D., Lacroix, A., Arlt, W., Haak, H. R., Loli, P., Decoudier, B., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00193-6 · Cited by 90
Self-citation
Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group
Postlewait, L. M., Ethun, C. G., Tran, T. B., Prescott, J. D., Pawlik, T. M., Wang, T. S., Glenn, J. A., Hatzaras, I. S., Shenoy, R. S., Phay, J. E., et al. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2015.12.013 · Cited by 87
Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art
Paragliola, R. M., Torino, F., Papi, G., Locantore, P., & Pontecorvi, A. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.62 · Cited by 85
Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma
Mohan, D. R., Lerário, A. M., Else, T., Mukherjee, B., Almeida, M. Q., Vinco, M., Rege, J., Mariani, B. M. P., Zerbini, M. C. N., Mendonca, B. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2693 · Cited by 84
Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis
Tang, Y., Liu, Z., Zou, Z., Liang, J., Lu, Y., & Zhu, Y. (2018) · BioMed Research International · doi:10.1155/2018/9362108 · Cited by 67
Adrenocortical Carcinoma
Baudin, É. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.03.001 · Cited by 66
Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)
Stigliano, A., Chiodini, I., Giordano, R., Faggiano, A., Canu, L., Casa, S. D., Loli, P., Luconi, M., Mantero, F., & Terzolo, M. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0349-9 · Cited by 61
Self-citation
Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence
Amini, N., Margonis, G. A., Kim, Y., Tran, T. B., Postlewait, L. M., Maithel, S. K., Wang, T. S., Evans, D. B., Hatzaras, I. S., Shenoy, R. S., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4810-y · Cited by 59
Future directions in the diagnosis and medical treatment of adrenocortical carcinoma
Creemers, S. G., Hofland, L. J., Korpershoek, E., Franssen, G. J. H., van Kemenade, F. J., de Herder, W. W., & Feelders, R. A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0452 · Cited by 61
Self-citation
Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence
Calabrese, A., Basile, V., Puglisi, S., Perotti, P., Pia, A., Saba, L., Berchialla, P., Porpiglia, F., Veltri, A., Volante, M., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0923 · Cited by 59
Self-citation
Diagnosis, treatment and outcome of adrenocortical cancer
Mihai, R. (2015) · British journal of surgery · doi:10.1002/bjs.9743 · Cited by 56
A nomogram for individualized estimation of survival among adult patients with adrenocortical carcinoma after surgery: a retrospective analysis and multicenter validation study
Kong, J., Zheng, J., Cai, J., Wu, S., Diao, X., Xie, W., Chen, X., Liao, C., Yu, H., Fan, X., et al. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0426-0 · Cited by 53
Adrenocortical carcinoma in children: First population-based clinicopathological study with long-term follow-up
Kerkhofs, T. M. A., Ettaieb, M. H. T., Verhoeven, R. H. A., Kaspers, G. J. L., Tissing, W. J. E., Loeffen, J. L. C., van den Heuvel‐Eibrink, M. M., de Krijger, R. R., & Haak, H. R. (2014) · Oncology Reports · doi:10.3892/or.2014.3506 · Cited by 52
Self-citation
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients
Cosentini, D., Badalamenti, G., Grisanti, S., Basile, V., Rapa, I., Cerri, S., Spallanzani, A., Perotti, P., Musso, E., Laganà, M., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0570 · Cited by 47
Self-citation
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma
Fiorentini, C., Grisanti, S., Cosentini, D., Abate, A., Rossini, E., Berruti, A., & Sigala, S. (2019) · Journal of Oncology · doi:10.1155/2019/6072863 · Cited by 45
Self-citation
Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
Puglisi, S., Calabrese, A., Basile, V., Ceccato, F., Scaroni, C. M., Simeoli, C., Torlontano, M., Cannavò, S., Arnaldi, G., Stigliano, A., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111850 · Cited by 45
Self-citation
Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
Basile, V., Puglisi, S., Calabrese, A., Pia, A. R., Perotti, P., Berruti, A., Reimondo, G., & Terzolo, M. (2020) · Cancers · doi:10.3390/cancers12092615 · Cited by 44
Self-citation
Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study
Wu, L., Huang, X., Kuang, Y., Xing, Z., Deng, X., & Luo, Z. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s209947 · Cited by 43
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options
Puglisi, S., Perotti, P., Cosentini, D., Roca, E., Basile, V., Berruti, A., & Terzolo, M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1510325 · Cited by 42
Self-citation
Therapeutic Targets for Adrenocortical Carcinoma in the Genomics Era
Mohan, D. R., Lerário, A. M., & Hammer, G. D. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00197 · Cited by 42
Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
Puglisi, S., Calabrese, A., Basile, V., Ceccato, F., Scaroni, C. M., Altieri, B., Casa, S. D., Loli, P., Pivonello, R., Martino, M. C. D., et al. (2020) · Cancers · doi:10.3390/cancers12030740 · Cited by 41
Self-citation
Practical treatment using mitotane for adrenocortical carcinoma
Terzolo, M., Zaggia, B., Allasino, B., & Francia, S. D. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000056 · Cited by 40
Self-citation
Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study
Kimpel, O., Bedrose, S. S. D., Megerle, F., Berruti, A., Terzolo, M., Kroiß, M., Mai, K., Dekkers, O. M., Habra, M. A., & Faßnacht, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01513-8 · Cited by 38
Self-citation
Curative Surgical Resection of Adrenocortical Carcinoma
Kim, Y., Margonis, G. A., Prescott, J. D., Tran, T. B., Postlewait, L. M., Maithel, S. K., Wang, T. S., Glenn, J. A., Hatzaras, I. S., Shenoy, R. S., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001527 · Cited by 37
Prognostic Factors of Adrenocortical Carcinoma: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database
Wang, S., Chen, S., Gao, W., Bai, L., Luo, L., Zheng, X.-G., & Luo, Y. (2017) · PubMed Central · doi:10.22034/apjcp.2017.18.10.2817 · Cited by 37
Pediatric adrenocortical tumor – review and management update
Balderrama-Brondani, V., & Fragoso, M. C. B. V. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000540 · Cited by 35
Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro
Theile, D., Haefeli, W. E., & Weiß, J. (2014) · Endocrine · doi:10.1007/s12020-014-0517-2 · Cited by 34
Identification of Mutations in Cell-Free Circulating Tumor DNA in Adrenocortical Carcinoma: A Case Series
Creemers, S. G., Korpershoek, E., Atmodimedjo, P. N., Dinjens, W. N. M., van Koetsveld, P. M., Feelders, R. A., & Hofland, L. J. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00174 · Cited by 33
Self-citation
Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study
Weigand, I., Altieri, B., Lacombe, A. M. F., Basile, V., Kircher, S., Landwehr, L., Schreiner, J., Zerbini, M. C. N., Ronchi, C. L., Megerle, F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa293 · Cited by 31
Self-citation
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer
Roca, E., Berruti, A., Sbiera, S., Rapa, I., Oneda, E., Sperone, P., Ronchi, C. L., Ferrari, L., Grisanti, S., Germano, A., et al. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0095 · Cited by 30
Self-citation
Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies
Iacono, M. L., Puglisi, S., Perotti, P., Saba, L., Petiti, J., Giachino, C., Reimondo, G., & Terzolo, M. (2021) · Cancers · doi:10.3390/cancers13215255 · Cited by 30
Self-citation
ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma
Terzolo, M., & Faßnacht, M. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0260 · Cited by 30
Self-citation
Medical Approaches in Adrenocortical Carcinoma
Paragliola, R. M., Corsello, A., Locantore, P., Papi, G., Pontecorvi, A., & Corsello, S. M. (2020) · Biomedicines · doi:10.3390/biomedicines8120551 · Cited by 29
The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition
Scheidt, H. A., Haralampiev, I., Theisgen, S., Schirbel, A., Sbiera, S., Huster, D., Kroiß, M., & Müller, P. K. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.03.022 · Cited by 28
Primary site surgery for metastatic adrenocortical carcinoma improves survival outcomes: an analysis of a population-based database
Wang, S., Gao, W., Chen, S., Bai, L., Luo, L., Zheng, X.-G., & Luo, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s147352 · Cited by 28
Management of adrenocortical carcinoma: are we making progress?
Kiesewetter, B., Riss, P., Scheuba, C., Mazal, P. R., Kretschmer‐Chott, E., Haug, A. R., & Raderer, M. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211038409 · Cited by 27
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging
Haider, M. S., Ahmad, T., Gröll, J., Scherf‐Clavel, O., Kroiß, M., & Luxenhofer, R. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00700-5 · Cited by 28
Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?
Gontijo, A. V. L., Pereira, S. L., & Bonfante, H. D. L. (2021) · Current Microbiology · doi:10.1007/s00284-021-02693-5 · Cited by 24
Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors
For Comete-Cancer Network, Vezzosi, D., Cao, C. D., Hescot, S., Bertherat, J. Y., Haissaguerre, M., Bongard, V., Drui, D., de la Fouchardière, C., Illouz, F., et al. (2017) · Hormones and Cancer · doi:10.1007/s12672-017-0313-6 · Cited by 23
Self-citation
Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study
Berruti, A., Libé, R., Laganà, M., Ettaieb, H., Sukkari, M. A., Bertherat, J. Y., Feelders, R. A., Grisanti, S., Cartry, J., Mazziotti, G., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0026 · Cited by 23
Self-citation
Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma
Kroiß, M., Plonné, D., Kendl, S., Schirmer, D., Ronchi, C. L., Schirbel, A., Zink, M., Lapa, C., Klinker, H., Faßnacht, M., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0946 · Cited by 23
microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma
Kwok, G., Zhao, J., Glover, A. R., Gill, A. J., Clifton-Bligh, R. J., Robinson, B. G., Ip, J. C. Y., & Sidhu, S. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0849 · Cited by 24
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
Cremaschi, V., Abate, A., Cosentini, D., Grisanti, S., Rossini, E., Laganà, M., Tamburello, M., Turla, A., Sigala, S., & Berruti, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2106128 · Cited by 21
Self-citation
The efficacy of radiation therapy in adrenocortical carcinoma
Luo, Y., Chen, S., Zheng, X.-G., Luo, L., & Wang, S. (2017) · Medicine · doi:10.1097/md.0000000000006741 · Cited by 21
The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
van Koetsveld, P. M., Creemers, S. G., Dogan, F., Franssen, G. J. H., de Herder, W. W., Feelders, R. A., & Hofland, L. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz001 · Cited by 21
Self-citation
A Micellar Mitotane Formulation with High Drug‐Loading and Solubility: Physico‐Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models
Haider, M. S., Schreiner, J., Kendl, S., Kroiß, M., & Luxenhofer, R. (2019) · Macromolecular Bioscience · doi:10.1002/mabi.201900178 · Cited by 21
Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients
Maiter, D. M., Bex, M., Vroonen, L., T'Sjoen, G. G., Gil, T., Banh, C., & Chadarévian, R. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.02.005 · Cited by 20
New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma
Stigliano, A., Cerquetti, L., Lardo, P., Petrangeli, E., & Toscano, V. (2017) · Oncology Reports · doi:10.3892/or.2017.5427 · Cited by 20
The clinical utility of ‘GRAS’ parameters in stage I–III adrenocortical carcinomas: long-term data from a high-volume institution
Liang, J., Liu, Z.-H., Zhou, L., Tang, Y., Zhou, C., Wu, K., Zhang, F., Zhang, F., Wei, X., Lu, Y., et al. (2019) · Endocrine · doi:10.1007/s12020-019-02141-2 · Cited by 20
Open vs laparoscopic adrenalectomy for localized adrenocortical carcinoma
Kaštelan, D., Knežević, N., Zibar, K., Alduk, A., Kakarigi, L., Kaštelan, M., Ćorić, M., Skoric‐Polovina, T., Solak, M., Kraljević, I., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14251 · Cited by 20
Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy
Ghorayeb, N. E., Rondeau, G., Latour, M., Cohade, C., Olney, H. J., Lacroix, A., Perrotte, P., Sabourin, A., Mazzuco, T. L., & Bourdeau, I. (2016) · Medicine · doi:10.1097/md.0000000000003180 · Cited by 20
Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells
Kroiß, M., Sbiera, S., Kendl, S., Kurlbaum, M., & Faßnacht, M. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0273-2 · Cited by 19
Rak kory nadnercza (ACC) — przegląd piśmiennictwa i doświadczenia własne
Dorota Dworakowska, B., Drabarek, A., Wenzel, I., Babińska, A., Świątkowska−Stodulska, R., & Sworczak, K. (2015) · Endokrynologia Polska · doi:10.5603/ep.2014.0069 · Cited by 19
Enzyme autoinduction by mitotane supported by population pharmacokinetic modeling in a large cohort of adrenocortical carcinoma patients
Arshad, U., Taubert, M., Kurlbaum, M., Frechen, S., Herterich, S., Megerle, F., Hamacher, S., Faßnacht, M., Fuhr, U., & Kroiß, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0342 · Cited by 19
Novel targeted therapies in adrenocortical carcinoma
Konda, B., & Kirschner, L. S. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000247 · Cited by 18
Adrenocortical Cancer Treatment
Long, S. E., & Miller, B. S. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.04.012 · Cited by 18
Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC
Warde, K. M., Schoenmakers, E., Martínez, E. R., Lim, Y. J., Leonard, M., Lawless, S. J., O’Shea, P. M., Chatterjee, K., Gurnell, M., Hantel, C., et al. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0031 · Cited by 18
In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆
Fragni, M., Lopez, L. P. P., Rossini, E., Abate, A., Cosentini, D., Salvi, V., Vezzoli, S., Poliani, P. L., Bosisio, D., Hantel, C., et al. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110585 · Cited by 16
Self-citation
Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring
Kerkhofs, T. M. A., Derijks, L. J. J., Ettaieb, M. H. T., Eekhoff, E. M. W., Neef, C., Gelderblom, H. A. J., den Hartigh, J., Guchelaar, H., & Haak, H. R. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0388 · Cited by 16
Self-citation
Antineoplastic Effect of a Combined Mitotane Treatment/Ionizing Radiation in Adrenocortical Carcinoma: A Preclinical Study
Cerquetti, L., Bucci, B., Carpinelli, G., Lardo, P., Proietti, A., Saporito, R., Rindi, G., Petrangeli, E., Toscano, V., & Stigliano, A. (2019) · Cancers · doi:10.3390/cancers11111768 · Cited by 16
Mitotane and Carney Complex: ten years follow-up of a low-dose mitotane regimen inducing a sustained correction of hypercortisolism
Campo, M. R., Lamacchia, O., Farese, A., Conserva, A., Picca, G., Grilli, G., & Cignarelli, M. (2014) · HORMONES · doi:10.14310/horm.2002.1514 · Cited by 16
Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options
Al-Ward, R., Zsembery, C., & Habra, M. A. (2022) · Endocrine Oncology · doi:10.1530/eo-22-0050 · Cited by 15
The effects of mitotane and 1α,25-dihydroxyvitamin D3 on Wnt/beta-catenin signaling in human adrenocortical carcinoma cells
Rubin, B., Pilon, C., Pezzani, R., Rebellato, A., & Fallo, F. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01127-1 · Cited by 15
The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients
Calabrese, A., Puglisi, S., Borin, C., Basile, V., Perotti, P., Pia, A. R., Berchialla, P., Volante, M., Fiori, C., Porpiglia, F., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad002 · Cited by 15
Self-citation
Diagnosis, treatment, and survival analysis of adrenocortical carcinomas: a multicentric study
Souteiro, P., Donato, S., Costa, C. F., Pereira, C. A., Simões‐Pereira, J., Oliveira, J. M., Belo, S., Santos, A. P., Cardoso, H., Leite, V. A. P. H., et al. (2019) · HORMONES · doi:10.1007/s42000-019-00161-1 · Cited by 14
Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series
Tõke, J., Uhlyarik, A., Lohinszky, J., Stark, J., Huszty, G., Micsík, T., Borka, K., Reismann, P., Horányi, J., Igaz, P., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.952418 · Cited by 14
A Review on Mitotane: A Target Therapy in Adrenocortical Carcinoma
Flauto, F., Martino, M. C. D., Vitiello, C., Pivonello, R., Colao, A., & Damiano, V. (2024) · Cancers · doi:10.3390/cancers16234061 · Cited by 12
Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma
Warde, K. M., Lim, Y. J., Martínez, E. R., Beuschlein, F., O’Shea, P. M., Hantel, C., & Dennedy, M. C. (2022) · Endocrinology · doi:10.1210/endocr/bqac102 · Cited by 12
Systemic therapy for adrenocortical carcinoma: a review
Johnson, J. E. H. (2020) · AME Medical Journal · doi:10.21037/amj.2020.01.07 · Cited by 11
Adrenocortical Carcinoma: Modern Management and Evolving Treatment Strategies
McDuffie, L. A., & Aufforth, R. (2016) · International Journal of Endocrine Oncology · doi:10.2217/ije-2015-0003 · Cited by 10
Identification of NDRG Family Member 4 (NDRG4) and CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) as Key Prognostic Genes in Adrenocortical Carcinoma by Transcriptomic Analysis
Yang, Z., Cheng, H. W., Zhang, Y., & Zhou, Y. (2021) · Medical Science Monitor · doi:10.12659/msm.928523 · Cited by 10
Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma
Allegra, S., Puglisi, S., Brescia, I. V., Chiara, F., Basile, V., Calabrese, A., Reimondo, G., & Francia, S. D. (2021) · Life · doi:10.3390/life11030266 · Cited by 10
Systemic Therapy in Locally Advanced or Metastatic Adrenal Cancers: A Critical Appraisal and Clinical Trial Update
Ferrari, L., Claps, M., Grisanti, S., & Berruti, A. (2015) · European Urology Focus · doi:10.1016/j.euf.2015.06.005 · Cited by 8
Self-citation
Corticosurrénalome : nouveautés en 2014
Libé, R., & Assié, G. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.01.009 · Cited by 8
Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane
Sbiera, S., Kendl, S., Weigand, I., Sbiera, I., Faßnacht, M., & Kroiß, M. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.009 · Cited by 7
Bilateral Aldosterone-Producing Adrenocortical Carcinoma: a Rare Entity
Daga, G., Sharma, S., & Mittal, V. (2016) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-016-0563-8 · Cited by 7
Lived experience of people with adrenocortical carcinoma and associated adrenal insufficiency
Yeoh, P., Czuber‐Dochan, W., Aylwin, S. J. B., & Sturt, J. A. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.341 · Cited by 7
Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience
Bronswijk, M. J., Laenen, A., & Bechter, O. E. (2019) · Neoplasma · doi:10.4149/neo_2019_190105n17 · Cited by 7
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion
Puglisi, S., Basile, V., Sperone, P., & Terzolo, M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09769-y · Cited by 7
Self-citation
Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study
Delbarba, A., Cosentini, D., Facondo, P., Laganà, M., Pezzaioli, L. C., Cremaschi, V., Alberti, A., Grisanti, S., Cappelli, C., Ferlin, A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1128061 · Cited by 6
Self-citation
Efficacy of EDP ± mitotane chemotherapy in the treatment of metastatic adrenocortical carcinoma. Predictive and prognostic factors of efficacy
Zhulikov, Y. А., Kovalenko, E. I., Bokhian, V., Khoroshilov, M. V., Gabrava, M. M., & Артамонова, Е. В. (2021) · Malignant tumours · doi:10.18027/2224-5057-2021-11-1-37-46 · Cited by 6
Glass transition, crystallization kinetics, and inter-conformer relaxation dynamics of amorphous mitotane and related compounds
Romanini, M., Valmaseda, A. P., & Macovez, R. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122390 · Cited by 6
Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics
Zhang, J., Wu, L., Su, T., Liu, H., Jiang, L., Jiang, Y., Wu, Z., Chen, L., Li, H., Zheng, J., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1365321 · Cited by 6
Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy
ALTIERI, B., Lalli, E., & Faggiano, A. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03601-0 · Cited by 5
Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study
Mormando, M., Galiè, E., Bianchini, M., Lauretta, R., Puliani, G., Tanzilli, A., Anceschi, U., Simone, G., Petreri, G., Graziano, G., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1222002 · Cited by 5
The impact of patient-, disease-, and treatment-related factors on survival in patients with adrenocortical carcinoma
Punjani, N., Clark, R. K., Izawa, J. I., Chin, J. L., Pautler, S. E., & Power, N. E. (2017) · Canadian Urological Association Journal · doi:10.5489/cuaj.4650 · Cited by 4
Management of adrenocortical carcinoma in Western Australia: a perspective over 14 years
Leong, D. C. W., Nyantoro, M., Shedzad, H., Robins, P. D., Henley, D., Ryan, S., Nguyen, H., & Lisewski, D. (2020) · ANZ Journal of Surgery · doi:10.1111/ans.16111 · Cited by 4
A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane
Liu, X., Fu, Q., Tang, Y., Deng, J., Mei, D., & Zhang, B. (2020) · Medicine · doi:10.1097/md.0000000000022620 · Cited by 4
Therapeutic frontiers in adrenocortical carcinoma: from standards to innovation
Schaap, D. M., Jie, E. X., Mayberry, T. G., Cowan, B. C., Wakefield, M. R., & Fang, Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02864-5 · Cited by 3
5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications
Rao, S. N., & Habra, M. A. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0247-9 · Cited by 3
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma
Chen, Y., Chen, J.-H., Shi, Y., Ling, X., Fang, S., Zhong, C., Liu, F., Zhong, W., Bi, X., Dong, Z., et al. (2024) · Endocrine Related Cancer · doi:10.1530/erc-23-0178 · Cited by 3
Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network
Faron, M., Naman, A. G., Delahousse, J., Hescot, S., Hadoux, J., Castinetti, F., Drui, D., Renoult-Pierre, P., Libé, R., Lamartina, L., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02439-7 · Cited by 3
Self-citation

Authors: Terzolo, M., Baudin, A. E., Ardito, A., Kroiss, M., Leboulleux, S., Daffara, F., Perotti, P., Feelders, R. A., deVries, J. H., Zaggia, B., De Francia, S., Volante, M., Haak, H. R., Allolio, B., Al Ghuzlan, A., Fassnacht, M., & Berruti, A.
Affiliations: Ospedale San Luigi Gonzaga (IT)
Universitätsklinikum Würzburg (DE)
Erasmus MC (NL)
Amsterdam UMC Location University of Amsterdam (NL)
Máxima Medisch Centrum (NL)
Corresponding author: Ardito, A
ORCID: Terzolo, M
Kroiss, M
Leboulleux, S
Feelders, R A
deVries, J H
Volante, M
Haak, H R
Fassnacht, M
Berruti, A
Venue: European Journal of Endocrinology
Publisher: Oxford University Press (OUP)
Published: 2013-09
Volume: 169
Issue: 3
Pages: 263-270
ISSN: 0804-4643 (ISSN-L)
1479-683X
DOI: 10.1530/eje-13-0242
OpenAlex: W2142931016
Cited by: 134
References: 31
Citations by year: 2026: 5 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 11 · 2021: 13 · 2020: 13 · 2019: 19 · 2018: 8 · 2017: 11 · 2016: 8 · 2015: 17 · 2014: 11 · 2013: 3
FWCI: 12.75
Type: journal article
Language: en
Open access: green
hdl.handle.net
Licence: other-oa
Locations: European Journal of Endocrinology (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Funders: Deutsche Krebshilfe
Regione Piemonte
Topics: Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords: adrenocortical carcinoma, mitotane, plasma drug concentration, adjuvant therapy, recurrence-free survival, overall survival, treatment response prediction, drug toxicity
MeSH terms: Adolescent, Adrenal Cortex, Adrenal Cortex Neoplasms, Adult, Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mitotane, Neoplasm Recurrence, Local, Neoplasm Staging, Retrospective Studies, Survival Analysis, Drug Monitoring, Chemotherapy, Adjuvant, Adrenocortical Carcinoma, Antineoplastic Agents, Hormonal, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks